O slideshow foi denunciado.
Utilizamos seu perfil e dados de atividades no LinkedIn para personalizar e exibir anúncios mais relevantes. Altere suas preferências de anúncios quando desejar.

Bone Marrow Transplant in Oncology

A brief presentation on Bone Marrow Transplant in Oncology by S K Rezaul, proudly presented by Biomedicz (www.biomedicz.com).

  • Entre para ver os comentários

Bone Marrow Transplant in Oncology

  1. 1. Bone Marrow Transplant in Oncology SK REJAUL DEPARTMENT OF BIOMEDICAL ENGINEERING NETAJI SUBHASH ENGINEERING COLLEGE
  2. 2. Source
  3. 3. Pathology  Treat Leukemia by chemotherapy  Regeneration of normal marrow  Chemotherapy alone cannot eliminate all malignant cells  Stem cell transplants.
  4. 4. Transplant  Patient's bone marrow stem cells are replaced with healthy cells  Existing bone marrow and abnormal leukocytes killed  Chemotherapy and radiation  Next bone marrow containing healthy stem cells re-infused
  5. 5. Procedure  Bone Marrow versus Peripheral Stem Cells  Accessibility  Cost  Sample size  Donor/Patient factors  Expertise
  6. 6. Adult Stem Cell Transplant
  7. 7. Procedure  Most blood stem cells reside in the bone marrow and a small number are present in the bloodstream  Multipotent peripheral blood stem cells  Can be obtained from drawn blood  PBSCs are easier to collect than bone marrow stem cells
  8. 8. Harvesting
  9. 9. Umbilical Cord Blood Stem Cell Transplant  Umbilical cords have traditionally been discarded as a by-product of the birth process.  Pluripotent-stem-cell-rich blood found in the umbilical cord rich in marrow stem cells and PBSC’s.
  10. 10. Umbilical Cord Tx  Umbilical cord transplants are less prone to rejection.  Cells have not yet developed the features that can be recognized and attacked by the recipient's immune system.  Umbilical cord blood lacks well- developed immune cells, there is smaller incidence of graft versus host disease.
  11. 11. Cord Blood
  12. 12. THE FUNCTION OF BMT UNIT Handling services & Intensive care for:  Mobilization / stem cell collection & infusion.  Chemotherapy for pre - transplant  Pre & post care for Transplant patients.
  13. 13. Transplantation     Autologous      Allogeneic      Syngeneic 
  14. 14. Indications  Hematological diseases Benign : Thallassaemia, Aplastic      Anaemia  Malignant : Leukemia Lymphoma         Myeloma  Immune deficiency disorders  Pediatric and Adult  Neurological Disease (MS)
  15. 15. Auto Transplant
  16. 16. Recovering from the transplant   Recovery of normal levels cells is called  engraftment  Day 8 - 12   Neutrophil engraftment important (GCSF)  may be given to accelerate the process  Platelets are the next to return with red  cells last.  Commonly patients require transfusion of  red cells and platelets following a  transplant.  Discharge upon neutrophil & platelet  engraftment
  17. 17. Allotransplant
  18. 18. Graft Verses Host Disease (GVHD)   GVHD sometimes occurs with allogeneic  transplantation.   Lymphocytes from the donor graft attack the cells of  the host  GVHD can usually be treated with steroids or other  immunosuppressive agents.   Acute GVHD occurs before day 100 post-transplant   Chronic GVHD occurs beyond day 100   Recent advances have reduced the incidence and  severity of this post-transplant complication, but  GVHD, directly or indirectly, still accounts for  approximately 15% of deaths in stem cell transplant  patients  Chronic GVHD can develop months or even years  post-transplant
  19. 19. GVHD  Skin/Hair Rash, scleroderma, lichenoid skin changes, dyspigmentation,alopecia  Eyes Dryness, abnormal Schirmer's Test, cornealerosions, conjunctivitis  Mouth Atrophic changes, lichenoid changes, mucositis,ulcers, xerostomia, dental caries  Lungs Bronchiolitis obliterans  GI tract Esophageal involvement, chronic nausea/vomiting, chronic diarrhea, malabsorption, fibrosis, abdomina l pain/cramps  Liver Abnormal LFTs, biopsy abnormalities  Genitourinary Vaginitis, strictures, stenosis, cystitis  Musculoskeletal Arthritis, contractures, myositis, myasthenia, fascities  Hematologic Thrombocytopenia, eosinophilia, autoantibodies
  20. 20. Transplantation  Unit is important  Expertise  Facility Isolation Phoresis Platelet and blood support Motivated patient
  21. 21. Problems  Intensive process that consumes resources  HIV  Donor registry limited  Other health care priorities

×